PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1443368
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1443368
Cholesterol-lowering Drug Market, By Drug class, By Disease type, By Distribution Channel, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
REPORT HIGHLIGHT
Cholesterol-lowering Drug Market size was valued at USD 18,400.87 Million in 2023, expanding at a CAGR of 3.4% from 2024 to 2032.
Cholesterol is categorized within the class of steroids, which are organic molecules and a type of lipids. It serves as a crucial structural component in the membranes of animal cells and is biosynthesized by all animal cells. The significance of cholesterol lies in its role in the biological synthesis of steroid hormones such as testosterone and estrogen, vitamin D, and bile acids. The primary sources of cholesterol production include poultry, meat, eggs, and dairy products. Elevated cholesterol levels can result from genetic diseases, obesity, an unhealthy diet, and various other medical conditions. The market for cholesterol-lowering drugs encompasses pharmaceuticals designed to decrease elevated cholesterol levels in the bloodstream, with a primary focus on reducing low-density lipoprotein (LDL) cholesterol. These drugs play a pivotal role in managing cardiovascular health by lowering the risk of atherosclerosis and related complications. As conditions like hypercholesterolemia and cardiovascular diseases become more prevalent globally, cholesterol-lowering drugs, such as statins, PCSK9 inhibitors, and bile acid sequestrants, are commonly prescribed to regulate cholesterol levels and mitigate the risk of heart-related conditions.
Cholesterol-lowering Drug Market- Market Dynamics
Increasing awareness of high cholesterol's adverse effects to propel market demand
The global Cholesterol-lowering Drug market is experiencing significant growth, driven by increasing awareness of high cholesterol's adverse effects. This growth has prompted manufacturers to conduct extensive investigational studies to identify well-tolerated drugs for improved patient outcomes. Furthermore, robust research and development activities in the sector, along with the incorporation of bempedoic acid for developing new drugs, contribute to the market's growth. The emergence of new drug classes catering to non-statin users is boosting market growth. However, the rising number of statin users and the endorsement of antihyperlipidemic adoption by various guidelines further propel market expansion. Elevated cholesterol levels increase the risks of stroke and myocardial infarction, while hypercholesterolemia is linked to increased vulnerability to cardiovascular diseases (CVD) and comorbidities like chronic kidney disease and type 2 diabetes. These factors act as additional drivers for market growth. The introduction of therapies such as bempedoic acid, PCSK9 inhibitors, and other drugs is expected to contribute to the market's continued expansion.
Cholesterol-lowering Drug Market- Key Insights
As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 3.4% over the forecast period (2024-2032)
Based on drug class segmentation, statins was predicted to show maximum market share in the year 2023
Based on disease type segmentation, hypercholesterolemia was the leading type in 2023
On the basis of region, North America was the leading revenue generator in 2023
Cholesterol-lowering Drug Market- Segmentation Analysis:
The Global Cholesterol-lowering Drug Market is segmented on the basis of Drug class, Disease type, Distribution Channel, and Region.
The market is divided into five categories based on drug class: combination drugs, PCSK9 inhibitors, cholesterol absorption inhibitors, bile acid sequestrants, and statins. The statins segment commands the largest portion of the global cholesterol-lowering drug market, primarily due to the introduction of effective therapies such as bempedoic acid and PCSK9 inhibitors.
The market is divided into four categories based on disease type: Hypercholesterolemia, Cardiovascular Diseases, Hyperlipidaemia, Others. Among the disease types in the cholesterol-lowering drug market, hypercholesterolemia stands out as a dominant focus. Hypercholesterolemia, characterized by elevated levels of cholesterol in the blood, is a primary target for cholesterol-lowering drugs due to its strong association with cardiovascular diseases. As a key contributor to atherosclerosis, hypercholesterolemia is a significant risk factor for heart-related conditions. Consequently, pharmaceutical companies are heavily invested in developing and marketing drugs, such as statins and PCSK9 inhibitors, specifically tailored to address hypercholesterolemia and mitigate the risk of cardiovascular events. The prevalence of hypercholesterolemia worldwide underscores its dominance in shaping the landscape of cholesterol-lowering drug development and market trends.
Cholesterol-lowering Drug Market- Competitive Landscape:
Recent Developments:
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL CHOLESTEROL-LOWERING DRUG MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032
GLOBAL CHOLESTEROL-LOWERING DRUG MARKET, BY DISEASE TYPE- MARKET ANALYSIS, 2019 - 2032
GLOBAL CHOLESTEROL-LOWERING DRUG MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032
GLOBAL CHOLESTEROL-LOWERING DRUG MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032
Table of Contents
1. Cholesterol-lowering Drug Market Overview
- 1.1. Study Scope
- 1.2. Market Estimation Years
2. Executive Summary
- 2.1. Market Snippet
- 2.1.1. Cholesterol-lowering Drug Market Snippet by Drug class
- 2.1.2. Cholesterol-lowering Drug Market Snippet by Disease type
- 2.1.3. Cholesterol-lowering Drug Market Snippet by Distribution channel
- 2.1.4. Cholesterol-lowering Drug Market Snippet by Country
- 2.1.5. Cholesterol-lowering Drug Market Snippet by Region
3. Cholesterol-lowering Drug Key Market Trends
4. Cholesterol-lowering Drug Industry Study
5. Cholesterol-lowering Drug Market: COVID-19 Impact Analysis
6. Cholesterol-lowering Drug Market Landscape
7. Cholesterol-lowering Drug Market - By Drug class
8. Cholesterol-lowering Drug Market - By Disease type
9. Cholesterol-lowering Drug Market - By Distribution channel
10. Cholesterol-lowering Drug Market- By Geography
11. Key Vendor Analysis- Cholesterol-lowering Drug Industry
12. 360 Degree Analyst View
13. Appendix
List of Tables
- TABLE List of data sources
- TABLE Market drivers; Impact Analysis
- TABLE Market restraints; Impact Analysis
- TABLE Cholesterol-lowering Drug Market: Drug class Snapshot (2023)
- TABLE Segment Dashboard; Definition and Scope, by Drug class
- TABLE Global Cholesterol-lowering Drug Market, by Drug class 2019-2032 (USD Million)
- TABLE Cholesterol-lowering Drug Market: Disease type Snapshot (2023)
- TABLE Segment Dashboard; Definition and Scope, by Disease type
- TABLE Global Cholesterol-lowering Drug Market, by Disease type 2019-2032 (USD Million)
- TABLE Cholesterol-lowering Drug Market: Distribution channel Snapshot (2023)
- TABLE Segment Dashboard; Definition and Scope, by Distribution channel
- TABLE Global Cholesterol-lowering Drug Market, by Distribution channel 2019-2032 (USD Million)
